1 Villanueva A. Hepatocellular Carcinoma. N Engl J Med. 2019;380:1450–62.
2 EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of hepatology. 2018;69:182–236.
3 World Health Organization. Projections of mortality and causes of death, 2016–2060.
4 Akinyemiju T et. al. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level. Results From the Global Burden of Disease Study 2015. JAMA Oncol. 2017;3:1683–91
5 International Agency for Research on Cancer. Known causes and prevention of human cancer by organ site. August 2016. http://monographs.iarc.fr /ENG/Publications/OrganSitePoster.pdf. Accessed August 7, 2017.
6 Forner et al. Hepatocelluar Carcinoma. Lancet. 2018;391:1301–14.
7 Llovet et al. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Disease. 1999;19(3):329–38.
8 Golfieri R et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer. 2014;111:255–64.
9 Inchingolo R et al. Locoregional treatments for hepatocellular carcinoma: Current evidence and future directions. World J Gastroenterol. 2019; 25(32):4614–28.
10 Llovet et al. Sorafenib in Advanced Hepatocellular Carcinoma. N Engl J Med 2008; 359:378–90.
11 Kudo et al. Lenvatinib vs Sorafenib in first-line treatment of patients with ; unresectable hepatocellular carcinoma: a phase 3 non-inferiority trial. Lancet. 2018;391:1163–73.
12 Finn et al. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. Journal of Hepatology. 2018;69:353–58.
13 Abou-Alfa et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018;379:54–63.
14 Zhu et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:282–9.
15 Yau et al. A Randomized, Multi-center Phase III Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (CheckMate 459: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 459. ESMO 2019; Annals of Oncology. 2019;30(suppl_5):v851–v934.
16 Finn et al. Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC). ASCO 2019. J Clin Oncol. 2019;37(15_suppl):4004–4004.
17 Finn et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382:1894–1905.
18 Cheng et al. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol. 2020;72:307–19.